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Available online 21 September 2016In the clinical setting, calculating cardiovascular disease (CVD) risk is commonplace but the utility of the
harmonised equation for metabolic syndrome (MetS) (Alberti et al., 2009) is less well established. The aims of
this study were to apply this equation to an overweight clinical cohort to identify risk factors for being metabol-
ically unhealthy and explore associations with chronic disease.
Baseline data were analysed from a lifestyle intervention trial of Illawarra residents recruited in 2014/2015. Par-
ticipants were aged 25–54 years with a BMI 25–40 kg/m2. Data included MetS, CVD risk, insulin sensitivity,
weight, body fat, diet, peripheral artery disease (PAD), physical activity, socio-economic position and psycholog-
ical proﬁle. Backward stepwise regression tested the association of covariates with MetS status and linear or lo-
gistic regression tested associations between MetS and risk of CVD, coronary heart disease, PAD and insulin
resistance. 374 participantswere included in the analysiswith 127 (34.0%) categorisedwithMetS. Covariates sig-
niﬁcantly and positively associated with MetS were higher BMI (odds 1.26, p b 0.01) and older age (odds 1.08,
p b 0.01). MetS participants (n= 351) had a 4.50% increase in CVD risk andwere 8.1 and 12.7 times (respective-
ly) more likely to be at risk of CHD and insulin resistance, compared to participants without MetS.
The utility of the harmonised equation in the clinical setting was conﬁrmed in this overweight clinical cohort.
Those classiﬁed as having MetS were more likely to be older, overweight/obese individuals and they had a sub-
stantially higher risk of developing CVD and insulin resistance than those without MetS.








A decline in metabolic health often precedes cardiovascular disease
(CVD)1 and diabetes mellitus, so there are beneﬁts in early identiﬁca-
tion and intervention. Deﬁnitions of “metabolically unhealthy” vary. In-
vestigators have frequently used either the absence of metabolic
syndrome (MetS), high insulin sensitivity, or a combination of both to
deﬁne metabolic health in overweight or obese individuals (Hinnouho
et al., 2013; Ärnlöv et al., 2010). A global deﬁnition of MetS now exists
(Alberti et al., 2009) that uniﬁes previously published equations with
an agreement that central obesity is not an obligatory component. The
harmonised deﬁnition of MetS is deﬁned as having three of the follow-
ing: elevated waist circumference (country speciﬁc guidelines), triglyc-
erides ≥1.7 mmol/L*, systolic blood pressure ≥130 or diastolic ≥85ry (ANZCTRN12614000581662).
Illawarra Health and Medical
Australia.
y mass index (BMI), ankle bra-
blood pressure (DBP), interna-
anxiety stress scale (DASS-21),
D).
. This is an open access article undermm Hg*, glucose ≥100 mg/dL and reduced HDL cholesterol b1.0
mmol/L (males) or b1.3 mmol/L (females) (or drug treatment as indi-
cated*) (Alberti et al., 2009). Recently published studies have also
been found to use previous MetS equations (Hinnouho et al., 2013;
Shab-Bidar et al., 2014; de Castro and Scorsatto, 2015).While risk calcu-
lations of CVD are readily available (D'Agostino et al., 2008; Wilson et
al., 1998), the identiﬁcation of MetS is not commonly used in practice
and could help initiate early intervention for disease prevention.
MetS often occurs in thepresence of obesitywhich is known to cause
a decline in life expectancy due to its associated metabolic and cardio-
vascular comorbid disorders. Clinical practice guidelines for obesity
defer to treatment with diet, physica activity and behavioural support
(Council NHaMR, 2013). However, recent research suggests that not
all obese individuals have the same metabolic risk proﬁle (Phillips,
2013) and this has implications for personalising treatment. In the
ﬁrst instance it may be relevant to distinguish individuals at high risk
for obesity-related metabolic diseases by identifying the presence of
MetS.
In addition to traditional risk factors such as obesity, many other fac-
tors have been suggested as being associatedwithMetS, such as chronic
stress (Epel et al., 2004); socioeconomic position (Brunner et al., 1997);
cardiorespiratory ﬁtness (LaMonte et al., 2005), peripheral arterythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Shab-Bidar et al., 2014). These all have implications for the mode of
treatment, particularly in relation to the nature of diet, exercise and psy-
chological support.
The aims of this study were to apply the harmonised equation for
calculation of MetS to a clinical cohort and to identify risk factors for
being metabolically unhealthy, as well as assess presence of MetS and
risk of chronic disease.
2. Methods
2.1. Study design and setting
This paper reports on a secondary analysis of data from the
HealthTrack study, a 12 month healthy lifestyle randomised clinical
trial. Participantswere randomised to receiving either usual care (general
advice), or individualised dietary advice with exercise prescription and
health coaching, with or without a healthy food supplement (walnuts).
Participants were recruited from the Illawarra region of NSW between
May 2014 and April 2015. Inclusion criteria for the study were: perma-
nent residents of the Illawarra region (NSW, Australia), adults aged 25–
54 years, and with a body mass index (BMI) in the range 25–40 kg/m2.
Exclusion criteria were: unable to communicate in English; severe medi-
cal conditions, impaired ability to participate; suffering from immunode-
ﬁciency; reported illegal drug use or regular alcohol intake (N50 g/day).
Ethical approval was granted by the University of Wollongong/Illawarra
Shoalhaven Local Health District Human Research Ethics Committee
(Health and Medical) (HE 13/189). Full written consent was obtained
prior to study commencement. The study is registeredwith the ANZ Clin-
ical Trial Registry (ANZCTRN12614000581662).
Full details of the protocol and methodology have previously been
described (Tapsell et al., 2015). In summary, at baseline 377participants
had body weight (kg) and %body fatmeasured using scales with a bio-
electrical impedance component. Fasting blood lipids (total cholesterol,
LDL, HDL, triglycerides) and blood glucose were collected and tested
through a registered pathology service (Southern IML Pathology). Sys-
tolic (SBP) and diastolic blood pressure (DBP) was measured using the
Omron BP-203RPEIII VP-1000 device (Omron Health Care, Kyoto,
Japan). Arterial stiffness (baPWV) and arterial occlusion (ankle brachial
index - ABI) data were also collected from this device, giving a direct
measure of peripheral artery disease. An ABI of b0.90 or N1.40was clas-
siﬁed as indicative of peripheral artery disease, ABI between 0.90 and
1.00 was classiﬁed as at risk of peripheral artery disease, and ABI be-
tween 1.01 and 1.39 was classiﬁed as healthy. Dietary intake was
assessed using 4 day food records completed by participants, which in-
cluded one weekend day. Dietary data was analysed using FoodWorks
software (Version 7, 2012, Xyris Software, Spring Hill, QLD, Australia).
Food intake data was converted to energy and macronutrient intake
using the AUSNUT2007 food composition database (AUSNUT, 2007).
Physical activity was assessed using the International Physical Activity
Questionnaire (IPAQ) short form survey questions (Craig et al., 2003)
and by a scientiﬁc grade pedometer (YamaxDigiwalker SW200, Pedom-
eters Australia)worn for 4 consecutive days to conﬁrman average num-
ber of steps per day. Psychological proﬁlewas assessed using the Physical
and Mental Quality of Life Assessment (SF-12) (Jenkinson et al., 2001)
and the Depression Anxiety Stress Scale (DASS-21) (Lovibond SHaPFL,
1995). Socio economic position was approximated by the use of level of
education attained and the average household income, which were
both self-reported in an on-line population survey completed during
screening for the randomised controlled trial. These covariates were in-
cluded in the analysis as they are related to the three components of the
lifestyle intervention which were implemented in the HealthTrack
study after the baseline assessment, those being: dietary counselling,
exercise advice and psychological coaching.
MetS was calculated using the harmonised deﬁnition (Alberti et al.,
2009), with waist circumference thresholds set at the AHA/NHLBI(ATP III) levels of ≥102 cm for males and ≥88 cm for females. Partici-
pants were categorised as MUO if MetS was present or MHO if no
MetS was present. Framingham CVD and coronary heart disease
(CHD) risk were calculated based on the published CVD equations
(D'Agostino et al., 2008) and CHD score sheets (Wilson et al., 1998). A
risk percentage of b10% was categorised as ‘low risk’, and 10% or more
were categorised as ‘moderate to high risk’ (b1% had a high risk of
CVD and CHD, therefore moderate and high risk categories were com-
bined). Similarly, for ABI the peripheral artery disease category
(≤0.90)was combinedwith the at risk category (0.91–1.00) for analysis.
Insulin resistancewas deﬁned as participants prescribed hypoglycaemic
agents or a glycated haemoglobin (HbA1c) level N6%.
2.2. Statistical analysis
The statistical package used for analysiswas IBMSPSS Statistics (ver-
sion 21.0, IBM Corp, Chicago IL, 2012). Analyses included baseline data
from all participants recruited into the HealthTrack study. The cross-
sectional associations between physiological and lifestyle covariates
and those classiﬁed as havingMetSwere analysed using backward step-
wise logistic regression. Covariates included demographic (age, BMI,
gender, % body fat); psychological (DASS-21, SF12 mental scale); phys-
ical activity (IPAQ, steps/day); dietary (total kilojoules, total fat, mono-
unsaturated fatty acid (MUFA), polyunsaturated fatty acid (PUFA) and
saturated fat); and social (education level, household income). Predic-
tors which achieved a p value b0.2 in univariate analysis were assessed
for inclusion in the multivariate model. The ﬁnal model was checked
using forward elimination (data not shown). Linear regression was
used to examine associations between incidence of MetS and CVD risk,
while logistic regression was used to test associations between MetS
and CHD risk, peripheral artery disease and insulin resistance.
3. Results
Of the 377 participants randomised, data required for calculation of
MetSwas available for 374, and 127 participants (34.0%)were classiﬁed
with MetS (Table 1). Multivariate analysis demonstrated that having a
higher BMI (odds 1.26, p b 0.01) and older age (odds 1.08, p b 0.01)
were signiﬁcantly and positively associated with having MetS (Table
2). None of the other psychological, physical, dietary or social factors
had a signiﬁcant association with MetS classiﬁcation.
To examine CVD and CHD estimated risk, data were available for
n= 351 participants (Table 3). The median risk of experiencing cardio-
vascular disease within the next 10 years for all participants (interquar-
tile range) was 3.89% (1.83–7.00). Most participants (88–92%) were in
the low risk (b10%) category. Using linear regression, participants clas-
siﬁed withMetS had a 4.50% increase in CVD risk compared to no-MetS
participants (odds 4.50 (95% CI: 3.72, 5.28), p b 0.01). Using logistic re-
gression, it was identiﬁed that MetS participants were 8.1 times more
likely to be at risk of CHD than others (odds 8.07 (95% CI: 3.16, 20.62),
p b 0.01).
A total of n= 26 (6.9%) of participants were categorised as being in-
sulin resistant (15 on prescribed hypoglycaemic medication, 11 with
HbA1c N6%). Using logistic regression, MetS participants were found
to be 12.7 times more likely to be insulin resistant (odds 12.73 (95%
CI: 4.28, 37.85), p b 0.01). In contrast, analysis of available data for
MetS and ABI (n = 372) found that MetS did not signiﬁcantly predict
peripheral artery disease (odds 0.91 (95% CI: 0.55, 1.51), p = 0.72).
4. Discussion
Obesity is a public health problem that contributes signiﬁcantly to
the increasing prevalence of chronic diseases such as diabetes mellitus
and CVD. However, given that metabolic risk may differ between
obese individuals, the identiﬁcation of those with MetS and the factors
associated with this risk may assist in developing approaches to
Table 1
Baseline characteristics of Illawarra (NSW, Australia) participants.
Baseline characteristic MetS (n = 127) No MetS (n = 247)
Demographic
Males/females (%) 33/67 23/77
Age (years) 45.8 ± 6.6 42.0 ± 8.5
Body mass index (kg/m2) 35.1 ± 3.9 31.3 ± 3.8
Body fat (%) (n = 371) 42.4 ± 6.6 39.4 ± 7.2
Metabolic
Systolic blood pressure (mm Hg) 135.0 ± 14.9 119.9 ± 12.7
HDL (mmol/L) 1.2 ± 0.3 1.5 ± 0.4
Total cholesterol (mmol/L) 5.4 ± 1.1 5.1 ± 0.9
Triglycerides (mmol/L) 1.8 ± 0.9 1.2 ± 1.3
Glucose (mmol/L) 6.0 ± 1.7 5.1 ± 0.6
Smoker/non-smoker (%) (n = 373) 5/95 4/96
Waist circumference (cm) 110.6 ± 10.3 99.9 ± 10.8
Psychological
DASS depression (%higha) 4.8 ± 4.3 (43.3) 4.0 ± 4.0 (34.8)
DASS anxiety (%higha) 3.1 ± 3.2 (32.3) 2.6 ± 2.8 (25.9)
DASS stress (%higha) 6.8 ± 3.9 (38.6) 6.5 ± 4.2 (37.2)
DASS total 14.6 ± 10.0 13.1 ± 9.2
SF 12 mental (n = 370) 46.3 ± 10.7 46.4 ± 9.6
Physical activity
IPAQ (MetS) (n = 368) 1396.7 ± 1514.3 1391.7 ± 1414.6
Steps/day (n = 294) 7012.1 ± 3030.2 7931.5 ± 3042.2
Dietary
Total energy (kJ) (n = 336) 9314.9 ± 2667.5 8861.6 ± 2343.9
Energy from fat (%) (n = 336) 34.7 ± 5.7 34.6 ± 5.0
MUFA (% of fat) (n = 336) 40.2 ± 4.8 40.6 ± 4.8
PUFA (% of fat) (n = 336) 16.4 ± 4.3 16.8 ± 4.6
Saturated fat (% of fat) (n = 336) 43.4 ± 6.7 42.6 ± 7.4
Social
University/post grad degree (%) 42 55
Household income b$80,000 (%) 27 24
Household income $80–159,999 (%) 45 43
Household income N$160,000 (%) 15 20
Income not recorded (%) 13 14
Pharmacological
Antihypertensive (%) 32.3 3.6
Hypolipidaemic (%) 15.0 5.3
Antidepressant/antianxiety (%) 22.0 14.2
Data are expressed as mean ± standard deviation or %.
a Proportion of high (includingmild, moderate, severe and extremely severe) scores of
depression ≥5, anxiety ≥4, and stress ≥8.
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to the onset of chronic disease. These analyses provided some insights
into who is at risk of having MetS and to what degree individuals with
MetS increase their risk of developing chronic disease. The application
of the harmonised equation proved useful in making this identiﬁcation
in an overweight clinical cohort that interestingly identiﬁed increased
risk in developing CVD, CHD and insulin resistance but not PAD (as
assessed using ABI). The latter may be due to the speciﬁcity of themea-
surement, and it was noted that most of the participants were at low
risk of CVD. These results highlight the gaps between assessment of
risk and the onset of disease, and this has implications for assessing out-
comes for lifestyle intervention.While it is appropriate to identify at risk
individuals and encourage lifestyle modiﬁcation, a focus on behaviour
changes and indications of reduced risk may be more appropriate than
reduced disease incidence.
The importance of measuring MetS in individuals has not been con-
ﬁrmed, however as prevention programs aim to address individuals
health issues before they develop into chronic disease, it may become
a vital assessment tool. Interest in themetabolic syndromewas high be-
tween 1997 and 2005, however since the most recent deﬁnition was
published in 2009 (Alberti et al., 2009), there appears to be a paucity
of data utilising the harmonised deﬁnition. Our study included healthy
participants aged between 25 and 54 years with a BMI in the range
24–40 kg/m2. It is well documented that overweight/obesity is themost important precursor for development of MetS (Ma and Zhu,
2013), so our participants represented those at greatest risk of MetS
and at a point of greatest beneﬁt from lifestyle change, the primary
treatment option. This sub-analysis of the HealthTrack clinical trial at
baseline demonstrated that amongst the many factors included in the
analysis, only older age and higher BMI predicted the presence of
MetS, as classiﬁed by the harmonised equation. As the development of
MetS begins with excess central adiposity, the ﬁndings were not sur-
prising, due to the prevalence of abdominal obesity in older overweight
individuals (Rutter et al., 2004). Still, our analysis conﬁrms the results of
previous studies that have reported BMI and age to be associated with
MetS (Alexander et al., 2008) in large national surveys using the ATPIII
criteria.
Those classiﬁed asMetS in this cohort were associated with a higher
percentage risk of developing CHD or CVDwithin the next ten years and
of developing diabetes mellitus; however we were not able to predict
peripheral artery disease, as indicated by ABI. The diagnosis of MetS is
reported to increase the risk of CVD by 30–400%, with the variation like-
ly due to differing deﬁnitions, populations studied, and length of follow-
up (Wannamethee et al., 2005; Lakka et al., 2002;Wilson et al., 2005). In
our cohort characterised by a lowprevalence ofmoderate-high CVD risk
(7–11%), those diagnosed with MetS had a 4.50% increase in CVD risk
and were eight times more likely to develop CHD within the next
10 years compared to participants without MetS. A low ABI has previ-
ously been reported in participants with MetS (Wild et al., 2006). We
did not ﬁnd an association between participants with MetS and low
ABI, but our study only contained a small proportion of participants di-
agnosed with peripheral artery disease.
Insulin resistancewas strongly associatedwithMetS in our analyses,
with a 12.7 times greater risk compared to individuals without MetS.
This ﬁnding is similar to another study examining obese subjects with
MetS that reported an adjusted relative risk of 10.3 for diabetes
(Meigs et al., 2006). These ﬁndings are expected as insulin resistance
is strongly and positively associated with BMI, most likely due to in-
creased liver and visceral fat content and the associated inﬂammatory
signalling (Kantartzis et al., 2010).
We also examined other lifestyle factors. The effect of psychosocial
stress on MetS appears to be reciprocal in that chronic stress induces
MetS as well as the associated hormonal dysfunctions of MetS augment
cortisol-induced stress (Brunner et al., 2002). More recently however,
the GEA study indicated that self-reported chronic stress did not predict
MetS (Ortega-Montiel et al., 2015). Our current analyses did not show
any signiﬁcant association between stress, anxiety, depression or quali-
ty of life and MetS. This may be due to the indirect methods used to as-
sess mental health, whichwere similar to that used in the GEA study. In
addition, Brunner et al. (2002) only demonstrated an association in
male participants, whereas our study sample was predominantly
female.
From a broader social perspective, lower social position has been
suggested as increasing the probability of MetS (Brunner et al., 1997),
as well as a low education level (Lee et al., 2005). In contrast, our anal-
yses found neither education level nor household income were signiﬁ-
cantly associated with MetS. The difference could be explained in
terms of larger sample sizes (n = 8104 and 4341 respectively vs n =
377), and different equations, but they also point to important differ-
ences in context. In the clinical decision making, education level and in-
comemaynot be as relevant as they are for population health strategies.
Physical activity is another important consideration. Low cardiore-
spiratory ﬁtness has been suggested as a predictor of MetS in a large co-
hort with BMI 22–25 kg/m2 (LaMonte et al., 2005). Our data did not
conﬁrm this ﬁndingwhichmay be due to the greater BMI of our clinical
cohort. From a dietary perspective, dietary fatty acids of vegetable origin
may have a beneﬁcial effect on the incidence of MetS (Shab-Bidar et al.,
2014). In our analyses no signiﬁcant association was found between di-
etary fatty acids and MetS, however the sample size was possibly too
small to detect these associations given variations in food choices.
Table 2
Baseline demographic and lifestyle covariates assessed in the multivariate logistic regression model of presence of MetS of Illawarra (NSW, Australia) participants.
Category Baseline variable Univariate analysis Multivariate analysis
Coefﬁcient Lower 95% CI Upper 95% CI p Odds Lower 95% CI Upper 95% CI p
Demographic Age 0.14 0.01 0.02 b0.01 1.08 1.04 1.12 b0.01
BMI 0.05 0.04 0.06 b0.01 1.26 1.18 1.36 b0.01
Gender −0.12 −0.23 −0.01 0.03 0.55 0.30 1.02 0.06
% body fat 0.01 0.01 0.02 b0.01 1.04 0.95 1.13 0.46
Psychological DASS depression 0.01 −b0.01 0.02 0.19 1.03 0.96 1.10 0.43
DASS anxiety 0.01 −0.01 0.03 0.21
DASS stress b0.01 −0.01 0.02 0.57
DASS total b0.01 −b0.01 0.01 0.23
SF-12 mental b0.01 −b0.01 0.01 0.82
Physical activity IPAQ b0.01 b0.01 b0.01 0.64
Steps/day S1# −0.26 −0.48 −0.03 0.02 0.62 0.19 2.01 0.43
Steps/day S2# −0.27 −0.46 −0.07 0.01 0.61 0.22 1.66 0.33
Steps/day S3# −0.20 −0.37 −0.04 0.02 0.65 0.28 1.49 0.31
Steps/day S4# −0.25 −0.41 −0.10 b0.01 0.55 0.25 1.18 0.12
Dietary Total kilojoules b0.01 b0.01 b0.01 0.12 1.00 1.00 1.00 0.23
MUFA − b 0.01 −0.01 0.01 0.56
PUFA − b 0.01 −0.02 0.01 0.46
Sat fat b0.01 −b0.01 0.01 0.39
Social Household income C1@ −0.09 −0.24 0.06 0.24
Household income C2@ −0.02 −0.14 0.10 0.75
Education L1* −0.25 −0.91 0.42 0.47
Education L2* −0.20 −0.86 0.46 0.56
Education L3* −0.10 −0.77 0.56 0.76
Education L4* −0.05 −0.74 0.64 0.89
Education L5* −0.22 −0.90 0.46 0.53
Education L6* −0.05 −0.73 0.63 0.89
Gender uses male as the referent category.#Steps/day S1 highly active, S2 active, S3 somewhat active, S4 low active. Steps per day are compared with sedentary as the referent category. @
Household income category C1 N$160,000, C2 $80–$159,999. Household income compared with b$80,000 as the referent category. *Education L1 postgraduate degree, L2 university de-
gree, L3 certiﬁcate/diploma, L4 trade/apprenticeship, L5 high school or leaving certiﬁcate, L6 school or intermediate certiﬁcate. Education levels are comparedwith no school certiﬁcate or
other qualiﬁcation as the referent category.
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tors were secondary outcome measurements and the sample size was
not speciﬁcally powered for addressing the relationships considered
here. Likewise, the HealthTrack population was generally healthy and
middle-aged albeit overweight, and this differed to other studies inves-
tigating younger or older populations. However from a public health
and primary healthcare perspective it is most important to identify
MetS in its earlier stages, that is, when people are healthy and before
they develop CVD or insulin resistance. One other limitation was the
use of medication, other than those included in the calculation of
MetS, CVD, CHD and insulin resistance; they were not adjusted for in
the multivariate analysis.5. Conclusions
This study examined the utility of the harmonised equation for as-
sessment of MetS in a clinical cohort of healthy overweight/obese vol-
unteers and conﬁrmed that those at greatest risk are older,
overweight individuals. OnceMetS is identiﬁed it is important to imple-
ment multi-disciplinary lifestyle changes due to the strong correlation
with cardiovascular disease and insulin resistance. The classiﬁcation of
MetSwill also be useful in determining the relative effects of lifestyle in-
tervention over time.Table 3
Estimated 10year cardiovascular disease (CVD) risk and coronaryheart disease (CHD) risk
(n = 351) of Illawarra (NSW, Australia) participants.
Risk category CVDa CHDb
Low (b10%) 310 (88.3%) 324 (92.3%)
Moderate (10–20%) 39 (11.1%) 26 (7.4%)
High (N20%) 2 (0.6%) 1 (0.3%)
a Based on published equation (D'Agostino et al., 2008).
b Based on published score sheets (Wilson et al., 1998).Conﬂicts of interest
Conﬂicts of interest: none.
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